Tradestie Institutional Equity Comparison Engine

IBD vs ISMD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ISMD Overall Edge

ISMD Captures Institutional Edge (1โ€“0 Pillars ยท 1โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Inspire Small/Mid Cap ETF (ISMD) driven by superior Momentum & Technical. Fundamentally, IBD trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ISMD at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, IBD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ISMD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
IBD N/M vs ISMD N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner ISMD
1Y -4.4% vs +23.2% ยท 52W Pos 26% vs 64%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBD NYSE Arca
Inspire Corporate Bond ETF
Institutional Equity
$23.10
-0.04% 1D
Market Cap N/A
1M Return -0.56%
1Y Return -4.39%
Forward P/E N/M
Unified AI Score
44.1 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 50.0 Mom 54.0
ISMD NYSE Arca
Inspire Small/Mid Cap ETF
Institutional Equity
$45.85
-1.46% 1D
Market Cap N/A
1M Return +0.5%
1Y Return +23.22%
Forward P/E N/M
Unified AI Score
42.0 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBD -4.39% ISMD +23.22% Spread: +27.61 pp (ISMD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IBD TTM Op. Margin: N/A ISMD TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBD vs ISMD. Trailing 12-month operating profitability (IBD N/A vs ISMD N/A) and valuation multiples (IBD N/M vs ISMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBD (2) vs ISMD (1)
Institutional Metric IBD ISMD Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 26% ($22โ€“$25) 64% ($36โ€“$52) Stronger Trend ISMD
Beta / 30D Volatility Risk Regime 0.11ฮฒ ยท 5% Vol 0.87ฮฒ ยท 22% Vol Lower Realized Risk IBD
Unified Institutional Score Composite Signal 44.1 / 100 (HOLD) 42.0 / 100 (HOLD) Higher Composite IBD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBD vs ISMD Buy Guide
IBD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ISMD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ISMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBD nor ISMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.